STAT+: Alnylam wins FDA approval for first drug to treat rare kidney disease
Alnylam Pharmaceuticals Inc. scored its third approval from the US Food and Drug Administration in as many years Monday, this time for a medicine to treat a rare disease that affects the kidneys.
The rare disorder — called primary hyperoxaluria type 1 — causes a buildup of oxalate in the body, which when not filtered properly can cause kidney and bladder stones.
Continue to STAT+ to read the full story…
